We have studied 39 patients doubly heterozygous for sickle cell/β-thalassemia, 12 with sickle cell/βo- thalassemia and 27 with sickle cell/β+-thalassemia. Generally, sickle cell/βo-thalassemia is considered more severe than sickle cell/β+-thalassemia. In our study, however clinical complications in the group with sickle cell/β+-thalassemia were seen almost as frequently as in the group with sickle cell/βo-thalassemia. A wide variety of clinical manifestations were seen in both groups of patients.
Maeda, Koichi; Van Slyck, Ellis J.; and Hawley, Robert C.
"Clinical and Laboratory Study of Sickle Cell/β-Thalassemia,"
Henry Ford Hospital Medical Journal
: Vol. 34
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol34/iss4/14